Part D: Patients must have measurable disease for Part D
Patients must have measurable disease
Measurable disease
Re-registration: measurable disease
Measurable disease
Patients must have measurable disease
Patients must have measurable disease
Documented metastatic disease (may be measurable or non-measurable)
Subjects must have measurable disease.
Measurable disease
Subjects with measurable disease.
Patients may have either non-measurable disease OR measurable disease
Have measurable disease
Patients must have at least one measurable site of disease
Measurable disease or non-measurable disease and refractory to or intolerant of existing therapies (Part 1)
Measurable disease
Part B: Patients must have measurable disease
Patients who do not have measurable disease on MRI
Measurable disease
Presence of measurable disease.
Measurable metastatic disease.
Patients must have measurable disease
Measurable disease
Patients must have measurable disease
Phase 1: patients may have measurable or non-measurable disease; measurable disease via RECIST 1.1 is required for Phase 2 patients
Measurable disease
Subjects must have measurable disease
Patients must have measurable disease.
Measurable disease
Measurable disease
Patients must have measurable disease
Must have measurable disease defined by:
Measurable disease
Subjects must have measurable disease
Measurable disease
Measurable disease in at least one site
Presence of measurable disease:
Measurable disease
Subjects with measurable or non-measurable lesions.
PHASE I: Patients may have measurable or non-measurable disease
Non-measurable disease only
Patients who have no measurable disease
Measurable disease or non measurable disease bone lesions in the absence of measurable disease as per RECIST 1.1
Measurable disease
Measurable disease
Measurable disease;
Measurable disease
Measurable disease.
Measurable disease
Measurable or non-measurable metastatic disease
Patient has measurable disease.
Patients must have at least one site of measurable disease
Measurable disease
Measurable disease
Measurable disease
Patients must have measurable disease
Measurable disease
Measurable disease
Measurable disease
Measurable disease required
Patients must have measurable disease
Measurable disease
Measurable disease
Has measurable disease
Measurable disease
Patients must have either measurable or evaluable limited-stage DLBCL          \r\n* Patients rendered free of measurable or evaluable disease by virtue of biopsy (resection) are also eligible; NOTE: if patient has measurable disease it must be documented on the Lymphoma Baseline Tumor Assessment Form\r\n* All measurable disease must be assessed within 28 days prior to registration\r\n* Patients with non-measurable disease with or without measurable disease must have all non-measurable disease assessed within 42 days prior to registration
Patients must have measurable disease
Has measurable disease
Subjects must have measurable disease
Subjects must have measurable disease
Measurable disease at time of enrollment
Measurable disease
Has measurable disease.
Measurable disease at screening
Must have measurable disease
Patient must have measurable disease or detectable (non-measurable) disease: Measurable disease will be defined by RECIST 1.1.
Measurable disease criteria:
Measurable disease
Measurable or non-measurable disease will be allowed, but only those with measurable disease will be evaluable for the response rate endpoint
Measurable disease
Measurable disease
Patients must have measurable disease
Participant has measurable and/or non-measurable disease
Measurable disease, requiring treatment
Both measurable as well as non-measurable disease will be allowed
Measurable disease
Patients must have measurable disease
Measurable disease
Measurable disease: measurable by gadolinium MRI scan
Measurable or non-measurable disease
Measurable disease
Measurable disease
Measurable disease
Measurable or non-measurable disease
Non-measurable or measurable disease
Measurable disease; note: disease that is measurable by physical examination only is not eligible
The patient has measurable disease
Measurable and non-measurable disease will be allowed
Patients must have measurable disease
Patients must have measurable disease at baseline
Measurable disease at the time of enrollment
Measurable disease
Patients may have measurable or non-measurable disease. x-rays and/or scans for disease assessment of measurable disease must have been completed within 28 days prior to registration; non-measurable disease must also be assessed within 28 days prior to registration; (expansion â€“ patients must have measurable disease)
Patients may have measurable or non-measurable disease; x-rays and/or scans for disease assessment of measurable disease must have been completed within 28 days prior to registration; non-measurable disease must also be assessed within 28 days prior to registration
Measurable disease
Patients must have measurable disease, defined as at least one tumor that is measurable
Measurable or non-measurable disease will be allowed
Subjects must have measurable disease
Measurable disease
Patients must have measurable disease:
Presence of measurable disease
Both measurable and non-measurable disease are allowed
Measurable disease
Measurable or non-measurable disease
Have measurable disease.
Measurable disease
Measurable disease;
Patients with measurable and non-measurable disease are eligible. Patients may or may not have cancer-related symptoms.
Participants do not need to have measurable disease; most patients will not have measurable disease at the time of treatment
Presence of measurable disease
Measurable disease
Patients must have disease that can be evaluated radiographically; this may be measurable disease or non-measurable disease; measurable disease is defined as that which can be measured in at least one dimension as >= 20 mm with conventional techniques, or >= 10 mm by high resolution imaging; disease that is identified on radiology studies, but does not meet the criteria for measurable disease, is considered non-measurable
Measurable disease
At least 1 measurable site of disease
Measurable disease.
Must have measurable disease defined as:
Must have measurable disease for Part A, measurable disease or non-measurable disease for Part B
Measurable or non-measurable disease will be allowed
Measurable tumor
Non-measurable or measurable, metastatic disease
Patients must have measurable disease
Patients may have either non-measurable disease OR measurable disease
Measurable disease
Measurable or non-measurable disease
Measurable disease
Measurable disease
Only evidence of disease is non-measurable.
Measurable or non-measurable disease
Patients must have measurable disease
May have measurable disease, non-measurable disease, or both.
Measurable disease
Measurable disease
Measurable or non-measurable disease that has progressed since last treatment.
Measurable disease
Measurable disease
Measurable or non-measurable disease
Patients must have measurable disease (Phase I)
Measurable disease
Patients must have measurable disease
Presence of measurable or non-measurable disease.
Measurable disease
Disease may be measurable or non-measurable
Measurable disease
At least one site of measurable disease
Measurable disease
Subjects must have measurable disease
Measurable disease.
Patients who only have non-measurable disease
Measurable Disease:
Measurable or non-measurable disease will be allowed
The participant has measurable or non-measurable disease.
Presence of measurable disease
Confirmed measurable disease
Patients must have measurable disease as defined by RECIST v. 1.1 criteria; baseline measurements and evaluation of ALL sites of disease must be obtained within 4 weeks prior to registration
One or more metastatic tumors measurable per RECIST Criteria
Measurable disease as per RECIST v1.1 criteria
Must have measurable disease per RECIST v1.1 Response Criteria
Measurable disease by RECIST 1.1 criteria
Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion
Have measurable or non-measurable disease per RECIST 1.1 criteria for solid tumors and RANO criteria for HGG
Measurable tumor lesions according to RECIST 1.1 criteria (Section 10.2).
Measurable disease by RECIST 1.1 criteria
Measurable disease as per RECIST v1.1 criteria
Patients must have at least 1 measurable metastatic lesion by RECIST1.1 criteria
Measurable disease, defined as per RECIST 1.1 criteria
Have measurable disease per RECIST 1.1 criteria present
Measurable disease by per RECIST 1.1 criteria; radiographic tumor assessment performed within 28 days of registration.
All patients enrolled will be required to have measurable disease by RECIST 1.1 criteria
Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion
New or increasing non-bone disease (RECIST 1.1 criteria);
Measurable disease by RECIST 1.1 criteria
Patients must have measurable disease by RECIST criteria
Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion.
Have measurable disease per RECIST 1.1 criteria present
Have measurable disease per RECIST 1.1 or irRECIST criteria present
Measurable disease as per the RECIST criteria v 1.1
Measurable disease according to PET Response Criteria, with the exception of patients with cutaneous disease that can be measured and followed by RECIST criteria
REGORAFENIB INCLUSION CRITERIA: Measurable disease by RECIST v1.1
ENTRECTINIB INCLUSION CRITERIA: Measurable disease by RECIST v1.1
Measurable disease as defined by RECIST v1.1 criteria. Baseline measurements and evaluation of ALL sites of disease must be obtained within 4 weeks prior to Enrollment.
Measurable disease as defined by RECIST 1.1 Criteria.
Measurable tumor lesions according to RECIST 1.1 criteria.[22]
Measurable tumor lesions according to RECIST 1.1 criteria.
Patients must have at least one measurable lesion per RECIST 1.1 criteria.
Patients must have measurable disease by the Modified RECIST criteria
Measurable disease defined by RECIST criteria
Patients must have measurable disease as defined by RECIST 1.1 criteria
Measurable disease as per RECIST 1.1 criteria.
Patients must have measurable disease per RECIST 1.1 criteria; all sites of disease must be evaluated within 4 weeks prior to randomization
Patients must measurable disease, as defined by RECIST 1.1 criteria
Measurable disease per RECIST 1.1 criteria
Have measurable disease per RECIST 1.1 criteria
Measurable disease according to RECIST 1.1 criteria.
Measurable disease by RECIST 1.1 criteria
Measurable disease is required for Part B expansion cohorts according to RECIST v1.1 criteria.
Progressive measurable disease: using conventional solid tumour criteria RECIST 1.1.
Disease must be measurable by RECIST 1.1 criteria
Subjects must have measurable disease by CT or MRI per RECIST 1.1 criteria (radiographic tumor assessment performed within 28 days of first dose of study drug) or clinically apparent disease that the investigator can follow for response per RECIST 1.1
Measurable disease per RECIST 1.1 criteria
Participants must have measurable disease by RECIST 1.1 criteria
Measurable non-CNS disease, defined by RECIST 1.1 criteria
Measurable disease as assessed by RECIST 1.1 criteria (Appendix A).
Measurable disease as defined by RECIST 1.1 criteria;
Measurable disease as assessed by modified RECIST for MPM and by RECIST 1.1 criteria for peritoneal mesothelioma, NSCLC, uveal melanoma, HCC, glioma and sarcomatoid carcinoma
Measurable disease by RECIST 1.1 criteria
Presence of at least one measurable lesion per RECIST 1.1 criteria
Measurable disease as defined by RECIST Criteria.
Measurable disease as defined by RECIST 1.1 criteria
Measurable disease by RECIST 1.1 criteria
Participants in the Phase II portion of the trial must have measurable disease by RECIST 1.1 criteria
Breast cancer participants must have measurable disease by RECIST criteria
For the Extension cohorts, patients must have measurable disease by RECIST criteria and meet the following disease-specific criteria:
Patients must have measurable disease (at least one measurable lesion) as defined by RECIST criteria; all sites of disease must be evaluated within 4 weeks prior to registration to treatment
Measurable disease by CT or MRI per RECIST 1.1 criteria
Measurable disease by RECIST 1.1 criteria.
Measurable disease at screening by RECIST 1.1 criteria
Patients must have measurable disease defined by RECIST criteria 1.1.
Measurable disease by RECIST v1.1 criteria
Measurable tumor lesions according to RECIST 1.1 criteria.[50]
Measurable disease as assessed by RECIST 1.1 criteria (Appendix A).
Have one or more metastatic tumors measurable on CT scan or locally advanced measurable disease that has clearly progressed after prior treatment per RECIST criteria.
Measurable disease by RECIST 1.1 criteria
Measurable disease as assessed by RECIST 1.1 criteria (Appendix A).
Measurable disease on baseline imaging per RECIST 1.1 criteria
Patients must have measurable disease by RECIST 1.1 criteria
Measurable disease, as defined by RECIST 1.1 criteria;
Subject has measurable disease according to RECIST v1.1 criteria.
Measurable disease per RECIST 1.1 criteria
Measurable disease according to RECIST v1.1 criteria
Measurable disease by RECIST criteria
Measurable disease according to RECIST 1.1 criteria.
Measurable disease as per RECIST v1.1 criteria
Measurable or non-measurable disease per RECIST version (v)1.1
Measurable disease according to RECIST criteria (Version 1.1)
Has measurable disease assessed by the investigator based on RECIST version 1.1.
Subjects must have at least one measurable target lesion according to RECIST version (v)1.1
At least 1 measurable target lesion according to RECIST version 1.1. CNS-only measurable disease as defined by RECIST version 1.1 is allowed.
Patient must have at least one measurable site of disease as defined by RECIST version (v)1.1, determined by investigator review
Measurable disease according to RECIST Version 1.1
Must have at least 1 site of measurable disease by RECIST criteria, by version 1.1
Measurable disease according to RECIST version (v)1.1 and obtained by imaging within 28 days prior to registration for protocol therapy; NOTE: A subject with prior brain metastasis may be considered if they comply with inclusion criteria below
Patients with at least one baseline measurable lesion according to RECIST criteria version 1.1.
Measurable disease per RECIST version (v)1.1.
Presence of measurable disease as defined by RECIST version 1.1 Cohort 4: Patient Population: Relapsed/Refractory Ovarian Cancer
Presence of measurable disease as defined by RECIST version 1.1
Measurable disease as per RECIST, version 1.1.
Measurable disease per RECIST version (v)1.1
Patients must have measurable disease as per RECIST (version 1.1)
Patients must have measurable disease by RECIST criteria version 1.1
For Part 1, cohorts 1-3: evaluable disease (per RECIST version 1.1). For Part 1, cohorts 4-6 and Parts 2 and 3: measurable disease (per RECIST version 1.1)
Have measurable disease per RECIST version 1.1.
Have measurable disease, as defined by RECIST version 1.1;
Measurable disease per RECIST version 1.1.
Has measurable disease based on RECIST version1.1
Subjects must have measurable disease according to RECIST (version 1.1)
Histologically-confirmed carcinoma of the breast (either the primary or metastatic lesions) for whom single-agent cytotoxic chemotherapy is indicated. Patients may have either measurable or non-measurable disease according to RECIST version 1.1.
Have measurable disease per RECIST version (v)1.1
Have measurable disease as per RECIST version 1.1; at least 1 of the tumor sites must be amenable to biopsy and this may not be the site of disease used to measure antitumor response
Participants must have at least 2 lesions with measurable disease as defined by RECIST Version 1.1
Participants must have measurable disease by RECIST version 1.1
Has at least one measurable lesion per RECIST version 1.1.
At least one measurable lesion based on RECIST version 1.1
FULL STUDY INCLUSION CRITERIA: Patients must have at least 1 measurable lesion according to RECIST version (v) 1.1
Measurable disease as defined by RECIST criteria (version 1.1)
Measurable target tumors using standard imaging techniques (RECIST version [v.] 1.1 criteria)
Patients must have disease that is measurable by RECIST version 1.1
Patient must have measurable disease as per RECIST version 1.1; at least 1 of the tumor sites must be amenable to biopsy and this may not be the site of disease used to measure antitumor response
Measurable disease as defined by RECIST version 1.1 by radiologic methods on or after the most recent line of therapy. For Cohort 2, imaging must be available for central review.
Measurable disease (revised RECIST; Version 1.1)
Measurable disease (revised RECIST; Version 1.1)
For Part 2, measurable disease as defined by RECIST, Version 1.1 including bone-only disease
For dose-escalation cohort, patient has at least 1 measurable disease as defined by RECIST criteria (Version 1.1). For dose-expansion cohort, patient has at least 1 measurable disease as defined by RECIST criteria (version 1.1) with a lesion larger than 1.5 cm that can be biopsied by core needle biopsy.
Measurable disease according to RECIST Version 1.1
At least one measurable site of disease in the liver according to RECIST version 1.1 and mRECIST criteria
COHORT EXPANSION PHASE: Patient must have measurable lesions as defined by RECIST version 1.1 criteria
Measurable disease as defined by RECIST version 1.1
Measurable disease, as defined by RECIST Version 1.1 (v1.1).
Measurable disease according to RECIST version 1.1.
Disease must be measurable with at least 1 uni-dimensional measurable lesion by RECIST Version 1.1 (including skin lesions)
Subjects must have measurable disease as defined per RECIST Version 1.1.
Demonstrated progression of disease by radiological or clinical assessment (Measurable disease according to RECIST Version 1.1 is NOT required for enrollment)
Subjects must have at least 1 measurable lesion based on RECIST version 1.1.
Measurable disease defined by RECIST version 1.1, or bone-only disease
Patients must have at least one measurable site of disease (according to RECIST [version 1.1] criteria)
Patients must have at least one measurable site of disease according to RECIST version 1.1 criteria
Measurable disease in accordance with RECIST version 1.1
At least 1 target lesion that is measurable by RECIST, Version 1.1
At least 1 target lesion that is measurable by RECIST, Version 1.1
Measurable disease according to the RECIST criteria (version 1.1), for the evaluation of measurable disease
Patient has measurable disease, as determined by the Investigator using RECIST, version 1.1, as determined within 28 days before baseline (C1D1).
Subject must have at least 1 unidimensional measurable NSCLC lesion on a CT scan as defined by RECIST (version 1.1).
Measurable disease, as defined by RECIST version 1.1
Presence of at least 1 measurable lesion according to RECIST version 1.1
PART B: Patients must have measurable disease as per RECIST version 1.1
Measurable disease according to modified RECIST version 1.1
Have evidence of measurable disease as defined by RECIST Version 1.1
Measurable disease according to RECIST version 1.1
Measurable disease by RECIST version 1.1
Subjects must have evidence of measurable disease per RECIST version 1.1 by radiographic techniques or magnetic resonance imaging
Measurable disease by RECIST version 1.1.
Tumors must have measurable disease as per RECIST (version 1.1);
At least one measurable lesion by CT scan or MRI based on RECIST version 1.1
Patient must have measurable lesions as defined by RECIST version 1.1 criteria
Measurable disease according to RECIST criteria (Version 1.1)
Patients must have measurable disease per RECIST criteria version (v.) 1.1
At least one lesion measurable by RECIST Version 1.1.
At least 1 unresectable lesion on a CT (Computerized Tomography) scan that is measurable as defined by RECIST, Version 1.1
Measurable disease (i.e., present with at least one measurable lesion per RECIST, version 1.1).
Measurable disease as per RECIST Version 1.1 criteria.
Measurable disease using RECIST criteria (version 1.1).
Measurable disease per RECIST version 1.1 (Arm A and B) and modified RECIST for Arm C.
Measurable disease at baseline in accordance with RECIST Version 1.1
Measurable disease as per RECIST guideline (Version 1.1);
Patients with measurable or non-measurable disease as determined by modified RECIST version 1.0 in dose-escalation phase, and patients with at least one measurable lesion as determined by RECIST 1.0 in expansion phase.
Measurable disease according to RECIST version 1.1.
Measurable disease at baseline as per RECIST version 1.1
Has at least one measurable lesion per RECIST version 1.1
Subjects must have measurable disease by RECIST Version 1.1.
Radiographic evidence of unidimensionally measurable disease; lesions will be considered measurable or non-measurable as per definitions provided in RECIST version 1.1
Histologically confirmed, metastatic TNBC with measurable disease per RECIST version 1.1.
Measurable disease per RECIST version 1.1.
Measurable disease as defined by RECIST v1.1
Patient much have measurable disease as defined by RECIST 1.1
Measurable disease as defined by RECIST v1.1
Measurable disease, as defined by RECIST v1.1
SAFETY RUN-IN: Have either evaluable disease, or have measurable clinical disease: measurable disease, defined as at least 1 unidimensionally measurable lesion on a computed tomography (CT) scan as defined by RECIST (version v1.1)
RANDOMIZED PHASE II CLINICAL TRIAL: Have measurable clinical disease: Measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT scan as defined by RECIST (version v1.1)
Measurable disease as defined by RECIST
Measurable disease as defined by RECIST 1.1 is required (Part 2)
Participants must have measurable extracranial disease as defined by RECIST 1.1
One or more tumors measurable on radiographic imaging as defined by RECIST 1.1.
Measurable disease, as defined by RECIST v1.1
Measurable disease, as defined by RECIST v1.1. At least one lesion accessible for biopsy
Participant must have measurable disease outside the field of radiation as defined by RECIST 1.1
Part B (all cohorts): Have the presence of measurable disease as defined by the RECIST 1.1.
Presence of at least one measurable lesion as defined by RECIST 1.1
Measurable disease, as defined by RECIST v1.1
Measurable disease as defined by RECIST 1.1
Measurable disease as defined by RECIST 1.1
Measurable or non-measurable disease, as defined by RECIST 1.1
Measurable disease as defined by RECIST v1.1
Most recent imaging shows measurable disease as defined by RECIST 1.1
Have measurable clinical disease: measurable disease, defined as at least 1 measurable lesion on a computed tomography (CT) scan as defined by RECIST (version v1.1)
Patients must have measurable disease as defined by RECIST v1.1
Radiologically measurable disease in the pancreas >= 1 cm, as defined by RECIST v1.1
Patients must have measurable disease as defined by RECIST (see Section 6).
All patients must have measurable disease as defined by RECIST 1.1; patients must also have evidence of disease progression by RECIST 1.1 within 6 months of first dose of study drug
Patients must have at least one measurable lesion as defined per RECIST 1.1
Subjects must have measurable disease as defined by RECIST 1.1
Patients may have measurable or non-measurable disease as defined by RECIST 1.1.
At least one measurable lesion as defined by RECIST 1.1
Patients may have measurable or non-measurable disease as defined by RECIST 1.1.
Measurable disease by CT or MRI, as defined by RECIST v1.1
Has ?1 measurable lesion as defined by RECIST 1.1 on imaging studies.
At least one measurable lesion as defined by RECIST 1.1
Patients must have at least one measurable or non-measurable lesion (dose escalation only) as defined by RECIST v1.1
Absence of RECIST, v. 1.1 defined measurable disease.
Participants must have at least a single (RECIST v1.1-defined) measurable lesion.
Subjects must have measurable disease as defined by RECIST 1.1
Measurable disease as defined by RECIST 1.1
Measurable/assessable disease, as defined by RECIST v1.1.
Measurable disease, as defined by RECIST v1.1
Patients must have measurable disease as defined by RECIST 1.1.
Measurable disease as defined by RECIST 1.1
Measurable disease defined as at least one uni-dimensional measurable lesion by CT or MRI according to RECIST 1.1
Measurable disease as defined by modified RECIST for MPM (Byrne and Nowak, 2004)
Measurable disease as defined by RECIST v1.1
Measurable disease as defined by RECIST 1.1
Measurable disease as defined by RECIST 1.1.
Patients must have measurable disease, defined by RECIST 1.1
Patients must have one or more tumors measurable on radiographic imaging as defined by RECIST.
Measurable disease, as defined by RECIST v1.1
Measurable disease, as defined by RECIST v1.1
Measurable disease, as defined by RECIST v 1.1
Has at least 1 radiologically measurable lesion as defined by RECIST 1.1
Measurable disease as defined by RECIST v1.1
Must have measurable disease as defined by RECIST 1.1.
Measurable disease, defined as at least 1 unidimensionally measurable lesion on a computed tomography (CT) scan as defined by RECIST 1.1
At least 1 measurable lesion as defined by RECIST v1.1
Measurable disease as defined by RECIST v1.1
Measurable disease as defined by RECIST v1.1
Measurable disease defined as one or more target lesions according to RECIST
Measurable disease defined by RECIST v1.1
Measurable disease as defined by the RECIST v1.1.
Patient must have measurable disease as defined by RECIST 1.1.
During the dose expansion part of study, all patients must have at least one measurable lesion as defined by RECIST criteria.
At least one measurable lesion as defined by RECIST v1.1
Measurable disease as defined by RECIST v1.1
Measurable disease as defined by RECIST 1.1 within 28 days prior to registration
Has At least one measurable lesion as defined by RECIST criteria
Measurable disease, as defined by RECIST v1.1
Presence of measurable or non-measurable lesions as defined by irRC-RECIST
Patients must have measureable hepatic disease and/or presence of vascular tumor thrombosis (involving portal vein, IVC and/or hepatic vein) which may not be measureable as per Response Evaluation Criteria in Solid Tumors (RECIST) on liver CT or MRI, within 28 days PRIOR TO STUDY ENTRY
Subject has progressive disease with at least one measureable lesion on MRI.
Histologic or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease per RECIST v1.1
Measureable disease as defined by the RECIST 1.1.
Measureable disease (defined as at least 1.5 cm in diameter).
Measureable disease per response evaluation criteria (RECIST) v1.1
For Part G, H, and I: Have measureable disease as defined by RECIST 1.1.
Patients enrolled in the expansion cohort must have at least one measureable lesion as defined by the RECIST 1.1 criteria
Has measureable disease by RECIST 1.1 criteria as assessed by the local site investigator/radiology.
Measureable or evaluable disease by RECIST v1.1 for solid tumors prior to the administration of study drug
Must have measureable disease as per RECIST Version 1.1 or RANO (for GBM).
Measureable disease according to RECIST Version 1.1
At least one measureable lesion as defined by RECIST version 1.1 that has not been previously irradiated
Measureable disease
Have measureable disease
At least one measureable tumor lesion that that has not been previously locally
Part 2 only: have measureable disease by RECIST
Measureable disease.
Measurable and/or non-measureable disease by RECIST criteria must be present
Patients with measureable or non-measureable disease are eligible
Measureable disease according to RECIST Version 1.1
Radiographically measureable disease.
Has measureable disease
Has measureable or nonmeasurable disease as defined by RECIST 1.1 criteria.
Subjects must have measureable disease according to RECIST (version 1.1).
Radiographically measureable disease
Radiographically measureable disease
Radiographically measureable disease
Measureable (target) disease.
At least one measureable lesion by RECIST 1.1.
Have measureable disease per RECIST 1.1.
Subjects must have measureable disease as defined by RECIST 1.1 criteria or modified RECIST criteria
Subjects who have brain metastasis as the only measureable lesion
At least one measureable lesion as defined by RECIST version 1.1 that has not been previously irradiated.
At least one measureable lesion.
Measureable disease
Measureable disease
Chemoembolization is allowed if >= 4 weeks from study entry; there are 3 possible scenarios:\r\n* If patient has hepatic disease only: they need to have progressed in the liver since chemoembolization and have measureable disease by RECIST 1.1 in order to be eligible\r\n* If patient has hepatic and extrahepatic disease: they will need to have progressed inside OR outside the liver and have measureable disease by RECIST 1.1 in order to be eligible
Measureable disease according to RECIST Version 1.1
Presence of measureable disease based on RECIST v1.1
Subjects must have at least 1 lesion that is measureable using RECIST guidelines
Measureable disease per RECIST v1.1 prior to administration of study medication
Tumors in previously irradiated fields may be considered measureable if there is evidence of tumor progression after radiation treatment.
Patients must have measureable or evaluable disease
Objective, measureable, symptomatic organ involvement, defined as one or more of the following:
Measureable disease as per RECIST
Presence of at least one measureable tumor lesion is required
Patients who have no measureable disease by serologic or urine markers (detectable disease only by bone marrow or imaging scans)
Women with >= 2 cm clinically or radiologically measureable breast cancer
Previously untreated participants must have a measureable lesion on an imaging study
Subject must have measureable disease by RECIST 1.1.
Presence of measureable disease based on RECIST v1.1.
Measureable disease
Presence of measureable disease based on RECIST v1.1
Measurable disease by RECIST v1.1
Measurable disease by RECIST 1.1 (Phase 2 only)
Subject in Phase 2 only: must have measurable disease per RECIST 1.1.
4. Measurable disease per RECIST v1.1 and irRECIST;
Measurable disease by RECIST v1.1 with at least one measurable target lesion
Measurable disease per RECIST 1.1.
Dose Escalation: Evaluable or measurable disease according to RECIST v1.1 Expansion Cohort (additional 30 patients) Measurable disease according to RECIST v1.1.
Measurable disease by RECIST v1.1 with at least 1 measurable lesion;
Measurable disease per RECIST 1.1.
Measurable disease by RECIST 1.1
Subject has at least one measurable lesion per RECIST v1.1.
Measurable disease via RECIST
Subject must have measurable neoplastic disease according to the RECIST v1.1;
Measurable disease by RECIST v1.1
One site of measurable disease by RECIST 1.1
Participants must have measurable disease (RECIST 1.1)
Subjects must have measurable lesions (according to standard RECIST 1.1).
Baseline measurable disease as measured by RECIST v1. 1.
Has measurable disease per RECIST 1.1 as assessed by the investigator/radiology
Measurable disease per RECIST v1.1
Presence of measurable disease per RECIST v1.1.
Has measurable disease per RECIST 1.1 as determined by investigator
Phase 1a: measurable or non-measurable disease per RECIST v 1.1.
Phase 1b: measurable disease per RECIST v 1.1 (subjects with non-measurable disease are not eligible for Phase 1b).
At least 1 measurable lesion by RECIST 1.1
INCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED AT AN OUTSIDE CLIA CERTIFIED LOCATION): Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable disease by RECIST 1.1 is required
Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1.
Measurable disease per RECIST v1.1
Measurable disease per RECIST v1.1 by radiographic techniques
Presence of at least one measurable lesion according to RECIST v1.1.
Presence of at least one measurable lesion according to RECIST v1.1.
Measurable disease by RECIST 1.1
PHASE IB: Measurable disease according to RECIST v1.1
Measurable disease, according to RECIST, v1.1
Patients must have measurable disease according to RECIST 1.1
PART II: Patients must have measurable disease, per RECIST 1.1
Measurable disease as outlined in RECIST 1.1
Patients must have metastatic disease, per RECIST 1.1 for the evaluation of measurable disease.
Measurable or non-measurable disease according to RECIST v1.1 or RECIL 2017.
Measurable disease per RECIST 1.1
Measurable disease by RECIST 1.1
Measurable disease according to RECIST 1.1.
COHORT 3: ENDOMETRIAL CANCER: Patients must have measurable disease, per RECIST 1.1
Presence of measurable disease by RECIST 1.1
Presence of measurable disease per RECIST v1.1.
Measurable or non-measurable disease according to RECIST v1.1 or RECIL 2017.
Measurable disease by RECIST
For disease-specific cohort participants: measurable disease per RECIST v. 1.1
Phase 2: Participants must have measurable disease as per RECIST 1.1.
Have measurable disease per RECIST v1.1, assessed within 4 weeks prior to study entry
Measurable disease (RECIST 1.1)
Patients must have measurable soft tissue disease per RECIST 1.1
Measurable disease according to RECIST v1.1 within 28 days prior to randomization
Measurable disease per RECIST 1.1
Measurable disease according to RECIST 1.1 within 28 days prior to registration.
Measurable disease by RECIST 1.1
Measurable disease by CT or MRI as per RECIST 1.1. Bone-only disease is not permitted.
Measurable disease per RECIST v.1.1
Measurable disease according to RECIST 1.1.
Measurable disease per RECIST 1.1 (primary or metastases)
Measurable disease, according to modified RECIST 1.1 and irRECIST
Patients must have measurable disease according to RECIST 1.1
Measurable disease by RECIST 1.1
Presence of at least one measurable lesion according to RECIST v.1.1
Disease must be measurable by RECIST 1.1
Patients must have measurable disease as per RECIST v1.1
At least one measurable lesion of the disease on imaging (CT or MRI; RECIST 1.1)
Measurable or non-measurable disease according to RECIST v1.1 or RECIL 2017.
Subject has at least one measurable lesion according to RECIST 1.1.
Patient with measurable disease according to RECIST
Has measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology
Measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology.
Measurable Disease by RECIST v1.1
Measurable disease according to RECIST v1.1.
Measurable disease per RECIST v1.1 for patients with solid malignancies.
Measurable disease by RECIST 1.1 guidelines
For the expansion cohort only: measurable disease by RECIST v1.1 with at least one measurable target lesion
Measurable disease as assessed by modified RECIST for MPM for thoracic disease (Appendix A) and RECIST 1.1 for extra-thoracic disease (Appendix B).
Measurable disease according to RECIST 1.1 within 30 days prior to registration.
Participants must have measurable disease by RECIST 1.1
Presence of measurable disease according to RECIST 1.1
Patients must have measurable disease according to RECIST 1.1
Measurable disease according to RECIST v1.1
Measurable disease as per RECIST 1.1. Subject must have extracranial metastasis as measurable disease
Measurable lesions by RECIST v1.1
Patients must have measurable disease according to RECIST (v.1.1).
Radiologically measurable disease according to RECIST v1.1
Measurable disease per RECIST v1.1
One or more tumors measurable on CT scan per RECIST 1.1.
Measurable Disease per RECIST 1.1 as determined by the Investigator
Measurable disease on CT or MRI by RECIST 1.1.
Measurable disease by RECIST
Has measurable disease per RECIST 1.1 as assessed by BICR.
Subject must have either measurable disease or bone only non measurable disease, according to RECIST1.1
Measurable disease according to RECIST v1.1
Has measurable disease per RECIST 1.1 as assessed by the investigator/site radiologist.
Measurable disease per RECIST 1.1 guidelines.
Measurable disease per RECIST v1.1
Measurable disease per RECIST v1.1
Measurable disease according to RECIST v1.1
Measurable disease per RECIST v1.1
Presence of at least one measurable lesion according to RECIST v.1.1
Disease must be measurable by RECIST 1.1
Measurable disease, according to the RECIST v1.1
Non-measurable disease according to RECIST 1.1, with the exception of bone-only non-measurable disease.
Patients must not have measurable progressive disease (RECIST 1.1)
Measurable disease per RECIST v1.1 (see Appendix 3)
Presence of measurable disease per RECIST v1.1.
Cancer antigen-125 (CA-125) only disease without RECIST 1.1 measurable disease
Does not have measurable disease per RECIST 1.1
Disease must be measurable by RECIST 1.1
Measurable disease according to RECIST 1.1.
Measurable disease per RECIST v1.1.
Evidence of measurable disease per RECIST 1.1
Have measurable disease according to RECIST v1.1 obtained by imaging within 28 days prior to registration.
Measurable disease as per RECIST v1.1
Subjects must have at least one measurable lesion per RECIST 1.1
Presence of measurable lesions (RECIST V1.1)
Measurable disease according to RECIST 1.1
Patient has measurable disease by (RECIST).
Measurable disease according to RECIST v1.1
Patients must have RECIST v1.1 measurable disease
Measurable disease per RECIST 1.1 as determined by the investigator.
Disease must be measurable, with ?1 unidimensional measurable lesion per RECIST 1.1.
Measurable disease as per RECIST v. 1.1.
Presence of measurable disease per RECIST v1.1
Measurable disease according to RECIST v 1.1 obtained by imaging within 28 days prior to registration
Measurable disease as per RECIST 1.1
Measurable disease according to RECIST 1.1
Measurable disease per RECIST v1.1 (see Appendix 6)
Measurable disease per RECIST v1.1
Measurable disease by RECIST 1.1
Measurable disease per RECIST v1.1
Measurable disease as per RECIST v1.1
Measurable disease per RECIST v1.1
Subjects may have measurable or non-measurable disease according to RECIST 1.1.
Measurable disease per RECIST 1.1 guidelines. Cohort 2 may include up to 10 subjects with advanced MET amplified, G/GEJ/E adenocarcinoma with non-measurable tumor per RECIST v1.1
At least 1 site of disease measurable by RECIST ver1.1
At least one measurable or non-measurable lesion as per RECIST 1.1 criteria for patients in Phase Ib; Measurable disease as determined by RECIST v1.1 for Phase II patients
Measurable disease that can be monitored per RECIST throughout the course of study participation.
Patient must have either measurable disease by RECIST 1.1 or bone lesions in absence of measurable disease.
Measurable disease (per RECIST v1.1) prior to the start of first-line chemotherapy
Measurable disease by RECIST 1.1
Measurable disease as per RECIST 1.1
Disease that is measurable per RECIST v1.1
Measurable disease by RECIST v1.1 with at least one measurable target lesion
Measurable disease per RECIST 1.1
Measurable lesion by RECIST 1.1
ECOG performance status 0 or 1 5. Measurable disease per RECIST v1.1
Measurable disease as per RECIST v1.1
Measurable disease as per RECIST 1.1.
At least one measurable lesion per RECIST v1.1. However, breast cancer patients with only bone disease are also eligible.
Patient has progressive and measurable disease as per RECIST 1.1. or other appropriate hematological guidelines.
Patient has progressive and measurable disease as per RECIST 1.1 or other appropriate hematological guidelines.
Measurable disease per RECIST v1.1.
Measurable disease per RECIST 1.1
Patients must have at least one measurable site of disease according to RECIST 1.1 that has not been previously irradiated
Measurable disease by RECIST
At least one measurable disease site per RECIST v1.1.
Disease that is measurable per modified RECIST v1.1
Measurable radiographic evidence of disease according to RECIST v1.1
Measurable disease (by RECIST 1.1)
Measurable disease according to RECIST v1.1 prior to administration of study drug
Measurable disease by RECIST 1.1 with PCWG2 modifications
Measurable disease according to RECIST v1.1
Measurable disease per RECIST v 1.1
Measurable Disease per RECIST 1.1
Measurable disease by RECIST v1.1
Measurable disease per RECIST v1.1
Measurable disease as determined by RECIST 1.1
Measurable disease according to RECIST
Measurable disease at presentation with disease measurable by RECIST required in the phase II cohort
Measurable disease according to RECIST and obtained by imaging within 30 days prior to registration for protocol therapy.
Measurable disease by RECIST 1.1
For the expansion cohort only: measurable disease by RECIST v1.1 with at least one measurable target lesion
Have measurable disease per RECIST v.1.1.
Measurable disease per RECIST v1.1
Subjects must have at least one lesion that is measurable by RECIST v1.1
At least 1 measurable tumor lesion per RECIST v1.1 (exception: subjects in Part 1 are not required to present with measurable disease)
Evidence of measurable disease by RECIST 1.1
Tumor to be irradiated as measurable by RECIST 1.1 or PRC
Measurable disease according to RECIST v1.1
Measurable disease by RECIST 1.1
With the exception of patients with non-measurable neuroblastoma patients must have measurable disease as per RECIST 1.1
Presence of measurable (by RECIST v1.1) and active extracranial disease will be excluded; patients with measurable extra cranial disease by RECIST v1.1 will be eligible to enroll if sites of disease are stable and not considered to be active after discussion with the sponsor
The participant has measurable or non-measurable disease according to RECIST 1.0 guidelines.
Patients must have measurable disease per RECIST v. 1.1.
Evidence of measurable or evaluable non-measurable disease per RECIST, v1.1
Measurable or non-measurable, but evaluable disease using RECIST v1.1
Patients must have measurable or evaluable disease per RECIST 1.1 criteria
PART I: participants are required to have only evaluable disease (disease that is visible on imaging studies but does not meet RECIST criteria for measurable disease)
One or more measurable or nonmeasurable evaluable lesions per RECIST 1.1.
Patients must have measurable or evaluable disease as defined per the RECIST v1.1 except patients with mCRPC.
Patients in the dose escalation phase of the study must have measurable or evaluable disease according to RECIST 1.1 criteria
Patients must have measurable or evaluable disease per RECIST 1.1 criteria
Measurable or evaluable disease by RECIST v1.1
Evaluable disease per RECIST 1.1
Evaluable/measurable disease by RECIST
Radiologically measurable and clinically evaluable disease as per RECIST v1.1
Evaluable or measurable disease as defined by RECIST v1.1 may be enrolled in the dose escalation part; for the dose confirmation part, subjects must have measurable disease by RECIST v1.1 or biomarker for response.
Patient with a TP53wt locally advanced or metastatic solid malignancy and with measurable or non-measurable (but evaluable) disease as determined by RECIST 1.1 criteria.
Patients must have measurable or evaluable advanced and/or metastatic disease by RECIST 1.1.
Must have evaluable or measurable disease per RECIST 1.1
Evaluable disease by RECIST v1.1.
Confirmed diagnosis of one of the following, and must be measurable or evaluable per RECIST 1.1 (solid tumors) or Lugano (NHL):
Patients must have measurable or non-measurable disease that is evaluable per RECIST 1.1;
Phase 1: Participants must have either measurable or evaluable disease as per RECIST 1.1.
Must be determined to have metastatic or unresectable disease, as determined by treating physician; (must have at least evaluable disease, but does not need to be measurable disease by RECIST 1.1)
Evaluable or measurable disease based on RECIST 1.1 (50)
Have measurable or evaluable disease based on RECIST 1.1
Measurable and/or evaluable disease as per the RECIST criteria version (v) 1.1
Evaluable disease: 1. During Part 1, evaluable disease is required; measurable disease per RECIST v1.1 is recommended but not required, 2. Subjects enrolled in Part 2 must demonstrate measurable disease per the disease-specific criteria.
Measurable or evaluable disease by RECIST v1.1 (not required for the cPoP study)
Must have evaluable disease by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan, according to RECIST 1.1 (subjects with measurable disease per RECIST 1.1 or radiographically visible and evaluable disease). Subjects with only ascites or pleural effusion are excluded.
Measurable or evaluable disease; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1, with radiologic scans within 28 days of day 1, cycle 1; evaluable disease must include bone metastases (pleural effusions and ascites are not considered evaluable for this study)
Have evaluable disease by RECIST 1.1 and PCWG2 criteria
CA-125 only disease without RECIST 1.1 measurable or otherwise evaluable disease
Measurable disease by RECIST or evaluable disease (e.g., bone metastasis, or lesions which do not fulfill RECIST criteria for metastatic disease)
Has evaluable or measurable disease by RECIST v1.1 criteria
At least one measurable/evaluable lesion by RECIST v1.1
Measurable or evaluable disease per RECIST v1.1
Patient has evaluable disease by RECIST v1.1 (Appendix 3).
Existence of measurable or evaluable disease (as per RECIST 1.1 criteria).
Measurable or evaluable disease according to RECIST v1.1.
In Stage 1, evaluable disease per RECIST 1.1. In Stage 2, measurable disease.
Must have baseline measurable or evaluable disease per RECIST
Have measurable and/or evaluable disease by RECIST 1.1
Triple negative breast cancer patients: participants may have either measurable disease via RECIST 1.1 criteria or evaluable disease
Participants must have measurable disease that is evaluable as per RECIST v1.1
Subjects with solid tumors, with the exception of CRPC, must demonstrate measurable disease, per RECIST v1.1. NOTE: Subjects with NMC that do not meet the RECIST v1.1 criteria for measurable disease, but have evaluable disease may be considered for enrollment after discussion with the GSK medical monitor..
Measurable disease via RECIST v1.1 or non-measurable, evaluable disease with at least one evaluable bone lesion via RECIST v1.1
The subject has measurable disease or nonmeasurable, evaluable disease per RECIST 1.1. (NOTE: pleural effusions, ascites or other third fluid space are not evaluable diseases per RECIST 1.1).
Participants must have measurable disease by RECIST v1.1 or non-measurable, evaluable disease with atleast one evaluable bone lesion by RECIST v1.1 based on radiologic scans within 28 days of Day 1 of Cycle 1
Have measurable and/or evaluable disease based on RECIST 1.1.
Measurable or evaluable disease by RECIST 1.1
Measurable or evaluable non-measurable disease as assessed by the investigator according to RECIST v1.1 criteria
Evaluable disease as determined by RECIST 1.1
Subjects must have either measurable disease or bone-only non-measurable disease, evaluable according to RECIST 1.1
Evaluable or measurable disease, as assessed by RECIST v1.1
3. Evaluable disease, or measurable disease as assessed by RECIST version 1.1.
Measurable disease according to RECIST Version 1.1 or non-measurable evaluable disease
Evaluable or measurable disease per RECIST v1.1
Radiologically measurable and clinically evaluable disease as per RECIST v1.1
Meaurable or evaluable extra-cranial disease as defined by RECIST v 1.1
Evaluable or measurable disease per RECIST v1.1
Evaluable or measurable disease per RECIST v1.1
Measurable or evaluable disease by RECIST 1.1
Evaluable or measurable disease per RECIST v1.1
Evaluable or measurable disease per RECIST v1.1
Evaluable or measurable disease per RECIST v1.1
Patients must have presence of at least 1 lesion that is measurable or evaluable using RECIST v1.1.
Subject must have evaluable disease as per RECIST criteria.
Measurable disease or non-measurable but evaluable disease, according to the RECIST v1.1; Participants with peritoneal disease would generally be regarded as having evaluable disease and allowed to enter the trial
At least one measurable lesion and/or non-measurable disease evaluable according to RECIST v1.1 criteria
Measurable disease per RECIST 1.1 criteria. Subjects with non-measurable, but evaluable disease are also eligible for Part 1 of the study.
Measurable or evaluable (non-measurable) disease per RECIST guidelines version 1.1.
Measurable disease per RECIST guidelines (subjects with non-measurable, but evaluable disease are also eligible for the dose escalation portion of the study)
Evaluable disease or disease measurable per RECIST
Evaluable or measurable disease per RECIST, Version 1.1
Patient must be evaluable using RECIST 1.1 criteria
Evaluable disease or disease measurable per RECIST 1.1
